Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial [0.03%]
POSITIVE研究中断辅助内分泌治疗尝试妊娠的乳腺癌患者的生育预测性激素因素
Isabelle Demeestere,Samuel M Niman,Ann H Partridge et al.
Isabelle Demeestere et al.
Purpose: The POSITIVE trial showed that premenopausal women with breast cancer (BC) can safely pause adjuvant endocrine treatment (ET) to attempt conception. 74 % of patients conceived spontaneously or through assisted re...
Impact of germline BRCA1/2 status on outcomes for patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a systematic review and meta-analysis [0.03%]
BRCA1/2基因胚系状态对HR+/HER2-转移性乳腺癌患者使用CDK4/6抑制剂治疗结局影响的系统评价和meta分析
Michele Bottosso,Christian Zurlo,Federica Miglietta et al.
Michele Bottosso et al.
Background: Almost 60 % of breast cancers (BCs) diagnosed in germline BRCA1/2 mutation (gBRCAm) carriers are HR+/HER2-. Sparse data suggest limited CDK4/6 inhibitors benefit among gBRCAm carriers. However, prespecified su...
Impact of stereotactic body radiation therapy on systemic therapeutic line change in oligometastatic breast cancer [0.03%]
立体放射治疗对少数转移性乳腺癌全身治疗线改变的影响
Julie Leblanc,Alexandre de Nonneville,Camille Nicolas et al.
Julie Leblanc et al.
Effect of a machine learning prediction model on the false-negative rate of sentinel lymph node biopsy for clinically node-positive breast cancer after neoadjuvant chemotherapy [0.03%]
机器学习预测模型对新辅助化疗后临床淋巴结阳性乳腺癌哨兵淋巴结活检假阴性率的影响
Minyan Chen,Tianzi Hong,Yali Wang et al.
Minyan Chen et al.
Background: Machine learning (ML) models can be used to predict axillary pathological complete responses (pCRs) in clinically node-positive (cN+) breast cancer after neoadjuvant chemotherapy (NAC). We developed an ML mode...
Biomarkers of response and resistance to immune checkpoint inhibitors in breast cancer [0.03%]
乳腺癌免疫检查点抑制剂治疗的反应和抗性的生物标志物研究
Michelle Li,François Panet,Vittoria Barberi et al.
Michelle Li et al.
Immune checkpoint inhibitors (ICIs) have recently been approved in subsets of patients with breast cancer (BC). Currently, programmed death ligand 1 (PD-L1) immunohistochemistry is used as a biomarker of response for metastatic triple negat...
Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication model [0.03%]
结合PREDICT预后模型中的70基因特征对雌激素受体阳性早期乳腺癌的预后及治疗结果进行预测
Ellen G Engelhardt,Mary Ann E Binuya,Paul D P Pharoah et al.
Ellen G Engelhardt et al.
Background: The 70-gene signature (70-GS) has been shown to identify women at low-risk of distant recurrence who can safely forgo adjuvant chemotherapy. Incorporating this GS into the well-validated and widely used PREDIC...
Acute presentations in neoadjuvant chemotherapy/immune checkpoint inhibition for triple negative breast cancer: experiences and impact from real-world data [0.03%]
三阴性乳腺癌新辅助化疗/免疫检查点抑制剂治疗急性反应的现实世界数据及影响体验
Tim Cooksley,Safwaan Adam,Bence Nagy et al.
Tim Cooksley et al.
Background: Recent data showed benefit of the addition of immune checkpoint inhibitor (ICI) therapy to cytotoxic chemotherapy in the neoadjuvant setting for patients with early triple negative breast cancer. Acute present...
BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study [0.03%]
BEYOnG BEBT-209治疗HR阳性/HER2阴性晚期乳腺癌的I期临床研究：一项多中心、开放标签试验
Zhe-Yu Hu,Kegang Jiang,Can Tian et al.
Zhe-Yu Hu et al.
Purpose: Several cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have been approved for the treatment of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer...
Corrigendum to "Development and evaluation of a decision aid for women eligible for organized breast cancer screening according to international standards: A multi-method study" [Breast 73 (2024) 103613] [0.03%]
关于“根据国际标准符合组织乳腺癌筛查资格的女性决策辅助工具的开发与评估：一种多方法研究”[乳腺癌杂志第73卷(2024年),文章号103613]的勘误表
Sandrine Hild,Delphine Teigné,Damien Fairier et al.
Sandrine Hild et al.
Published Erratum
Breast (Edinburgh, Scotland). 2025 Jul 21:83:104529. DOI:10.1016/j.breast.2025.104529 2025
Outcomes, indications and predictive factors for complications in postmastectomy prepectoral reconstructions with polyurethane foam-coated implants [0.03%]
聚氨酯泡沫包被假体胸大肌下乳房再造的疗效、指征及并发症预测因素分析
Andrea Lisa,Francesca Riccardi,Mario Alessandri-Bonetti et al.
Andrea Lisa et al.
Background: Implant-based reconstruction (IBR) is the most common reconstructive strategy following mastectomy. Advancements in surgical techniques and materials have led to improvement in perfusion and thickness of maste...